Donald Trump Reiterates Warning Against Tylenol Use During Pregnancy, Citing FDA Inaction
President Donald Trump has once again urged pregnant women to avoid using Tylenol unless absolutely necessary, reigniting a debate over the safety of the common pain reliever during pregnancy. In a recent post on Truth Social, Trump also advised against giving Tylenol to young children and called for changes in the administration of childhood vaccines.
In the post, Trump wrote, “Pregnant women, don't use Tylenol unless absolutely necessary. Don't give Tylenol to your young child for virtually any reason. Break up the MMR shot into three totally separate shots (not mixed!). Take chicken pox shot separately, take hepatitis B shot at 12 years old or older, and, importantly, take vaccines in five separate medical visits!” — President DJT
In the post Trump attached a Daily Caller news article that said, the Food and Drug Administration (FDA) defied the advice of its own drug safety experts to warn pregnant women about Tylenol for nearly a decade, internal reports and presentations obtained by the Daily Caller News Foundation reveal.
“FDA rank-and-file scientists repeatedly recommended the agency release information about Tylenol in pregnancy across three scientific reviews conducted in 2016, 2019, 2022 and two memos, one from the FDA's maternal health division in 2016 and one from the FDA's urological health division in 2017,” it added.
Earlier on Sep 23, The Trump administration linked Tylenol to autism and urged pregnant women to avoid the common pain medication despite the lack of widely accepted scientific evidence supporting the risk.
“So taking Tylenol is not good — I'll say it — it's not good. For this reason, they are strongly recommending that women limit Tylenol use during pregnancy unless medically necessary,” Trump said at a White House event alongside Robert F. Kennedy Jr., his health secretary.
The administration also said it has initiated approval of leucovorin calcium tablets as a new treatment for a condition associated with autism. The drug, also known as folinic acid, is currently used to treat side effects of certain cancer drugs and anemia, Bloomberg reported.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.